{"filing":{"accession_number":"0001437749-26-025304","cik":"0001001316","ticker":"TGTX","company_name":"TG THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"tgtx20260730_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/tgtx20260730_8k.htm"},"events":[{"id":23397,"run_id":21150,"accession_number":"0001437749-26-025304","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"TG Therapeutics issued a press release on August 3, 2026, announcing financial results for the second quarter and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue figures ($235.8M and $437.1M in product revenue for Q2 and H1 2026), operating expenses, net income ($7.8M and $27.6M), and updated full-year 2026 revenue guidance raised to approximately $950 million. This is a standard earnings release disclosing results of operations and financial condition under Item 2.02.","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23609,"accession_number":"0001437749-26-025304","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"TG Therapeutics issued a press release on August 3, 2026, announcing financial results for the second quarter and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue figures ($235.8M and $437.1M in product revenue for Q2 and H1 2026), operating expenses, net income ($7.8M and $27.6M), and updated full-year 2026 revenue guidance raised to approximately $950 million. This is a standard earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:25:12.321781+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23609,"accession_number":"0001437749-26-025304","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"TG Therapeutics issued a press release on August 3, 2026, announcing financial results for the second quarter and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue figures ($235.8M and $437.1M in product revenue for Q2 and H1 2026), operating expenses, net income ($7.8M and $27.6M), and updated full-year 2026 revenue guidance raised to approximately $950 million. This is a standard earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:25:12.321781+00:00","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-08-03"}]}